Read by QxMD icon Read


A E Bautin, A S Iakovlev, D M Tashkhanov, S V Datsenko, A O Marichev, M A Popov, P A Fedotov
PURPOSE: To determine the specifics of inhaled iloprost effect on pulmonary and systemic hemodynamics in patients with pulmonary hypertension (PH) associated with left ventricular systolic dysfunction. MATERIALS AND METHODS: 47 vasore- activity tests (VRT) with 20 micrograms inhaled iloprost (Ventavis, Bayer) were performed in 39 candidates on heart transplantation. All patients had heart failure III-IV NYHA and PH with pulmonary vascular resistance (PVR) more than 2...
March 2015: Anesteziologiia i Reanimatologiia
Amitesh Agarwal, Alex Duarte
SESSION TITLE: Critical Care CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMPURPOSE: Treatment of Pulmonary arterial hypertension (PAH) with chronic intravenous prostanoid through a chronic tunneled catheter has been reported to be associated with bacteremia and sepsis; however bacterial endocarditis is rarely reported. Here we report a patient with idiopathic PAH receiving chronic intravenous prostacyclin that developed acute Clostridium perfringens aortic valve endocarditis...
March 1, 2014: Chest
Majdy M Idrees, Enas Batubara, Tarek Kashour
BACKGROUND: Right ventricular (RV) dysfunction has been identified as a poor prognostic indicator in sub-massive pulmonary embolism (SPE). We hypothesized that using selective vasodilator agent is beneficial in improving RV function in patients with this condition. METHODS: We used inhaled prostacyclin analogue (Iloprost, Ventavis(®)) in five patients with SPE. Helical computerized tomography angiogram was confirmatory for pulmonary embolism and echocardiography was used to evaluate the RV status...
July 2012: Annals of Thoracic Medicine
Ralf Ewert, Sven Gläser, Tom Bollmann, Christoph Schäper
Iloprost (Ventavis, Bayer Schering Pharma, Germany) is a synthetic prostacyclin that is used in its inhalative form for the therapy of pulmonary arterial hypertension. Long-term therapy can increase exercise capacity and quality of life. The use of modern nebulizers especially designed for the administration of iloprost guarantees the pulmonary deposition of the required doses and systematically minimizes side effects. Regarding existing data, inhalative iloprost acts in effective and safe combination with other classes of medication; indeed, such combination therapy is frequently necessary in pulmonary arterial hypertension...
April 2011: Expert Review of Respiratory Medicine
Vivek Gupta, Fakhrul Ahsan
This review summarizes the pathophysiology and current therapeutic and drug delivery strategies for pulmonary arterial hypertension (PAH), a rare but devastating disorder of the pulmonary circulation affecting 50,000 to 100,000 persons in the United States. Chief clinical features of PAH include increased mean pulmonary arterial pressure (>25 mm Hg) and right ventricular and smooth muscle hypertrophy. A wide variety of agents have been studied for use as anti-PAH drugs, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, to name a few...
2010: Critical Reviews in Therapeutic Drug Carrier Systems
T Wittwer, U F Franke, T Sandhaus, M Thiene, J Groetzner, J T Strauch, J Wippermann, M Ochs, C Muehlfeld
BACKGROUND: Optimal allograft protection is essential in lung transplantation to reduce postoperative organ dysfunction. Although intravenous prostanoids are routinely used to ameliorate reperfusion injury, the latest evidence suggests a similar efficacy of inhaled prostacyclin. Therefore, we compared donor lung-pretreatment using inhaled lioprost (Ventavis) with the commonly used intravenous technique. METHODS: Five pig lungs were each preserved with Perfadex and stored for 27 hours without (group 1) or with (group-2, 100 prior aerosolized of iloprost were (group 3) or iloprost (IV)...
June 2007: Transplantation Proceedings
Robert E Van Dyke, Kurt Nikander
BACKGROUND: Iloprost (Ventavis) inhalation solution is approved in doses of 2.5 microg and 5.0 microg for treatment of pulmonary arterial hypertension (World Health Organization group I) in patients with New York Heart Association class III or IV symptoms, delivered with 2 Adaptive Aerosol Delivery (AAD) systems: Prodose and I-neb. The HaloLite device was the first-generation AAD system used in the clinical delivery of inhaled iloprost, and I-neb is the third-generation system. OBJECTIVE: Study the in vitro performance of the HaloLite, Prodose, I-neb, in terms of mass median aerodynamic diameter (MMAD), fine-particle fraction (FPF, percent of aerosol droplets < 4...
February 2007: Respiratory Care
Thorsten Wittwer, Ulrich F W Franke, Tim Sandhaus, Jan Groetzner, Justus T Strauch, Jens Wippermann, Matthias Ochs, Christian Mühlfeld, Angelika Börner, Sibylle Streck, Thorsten Wahlers
BACKGROUND: Lung retrieval from non-heart-beating donors (NHBD) has been introduced into clinical practice successfully. However, because of potentially deleterious effects of warm ischemia on microvascular integrity, use of NHBD lungs is limited by short tolerable time periods before preservation. Recently, improvement of NHBD graft function was demonstrated by donor pre-treatment using aerosolized Ventavis (Schering Inc., Berlin, Germany). Currently, there is no information whether additional application of this approach in reperfusion can further optimize immediate graft function...
November 2006: Journal of Surgical Research
K Ahmadi-Simab, W L Gross
Pulmonary arterial hypertension (PAH) is a severe vasculopathy, which is characterised by progressive narrowing and obliteration of the pulmonary arterioles and increased endothelin-1 levels. The increase of vascular resistance in the lung vessels leads to chronic pressure overload and to right heart failure, if untreated. PAH often occurs in association with rheumatic-inflammatory diseases (e.g., in 15% of patients with systemic sclerosis (SSc), especially in the limited form or in CREST patients) and determines their prognosis: in advanced stages, untreated patients die within a short period...
July 2006: Zeitschrift Für Rheumatologie
Hans-Joachim Gais, Guido Johannes Kramp, Dennis Wolters, Leleti Rajender Reddy
We describe new fully stereocontrolled syntheses of the prostacyclin analogues iloprost (2), the most active component of the drugs Ilomedin and Ventavis, and 3-oxa-iloprost (3), a derivative that is expected to have a significantly higher metabolic stability than 2 perhaps allowing an oral application. The syntheses are based on the same strategy and chiral bicyclic building block as used in the synthesis of cicaprost (4), the third most potent analogue that exhibits, besides prostacyclin-like activities, antimetastatic activities...
July 17, 2006: Chemistry: a European Journal
Guido J Kramp, Mikhail Kim, Hans-Joachim Gais, Cornelia Vermeeren
In this article we describe fully stereocontrolled total syntheses of 16S-iloprost (16S-2), the most active component of the drugs Ilomedin and Ventavis, and of 16S-3-oxa-iloprost (16S-3), a close analogue of 16S-2 having the potential for a high oral activity, by a new and common route. The key steps of this route are (1) the establishment of the complete C13-C20 omega side chain of the target molecules through a stereoselective conjugate addition of the alkenylcopper derivative 9 to the bicyclic C6-C12 azoalkene 10 with formation of hydrazone 8, (2) the diastereoselective olefination of ketone 7 with the chiral phosphoryl acetate 39, and (3) the regio- and stereoselective alkylation of the allylic acetate 43 with cuprate 42...
December 21, 2005: Journal of the American Chemical Society
J Behr, M M Borst, J Winkler, M Hoeper, M Halank, A Ghofrani, H Klose, H Wilkens, G Stähler
For patients with pulmonary arterial hypertension (PAH) two first line therapies - iloprost inhalation (Ventavis) and bosentan (Tracleer) -- are available in Germany. A third substance, sildenafil, is already approved in the US and will be approved for this indication in the European Union soon. Patients with PAH can be stabilized or improved with a specific mono-therapy for a limited period of time only. Therefore, the question arises when and how to initiate treatment escalation. The available data from controlled clinical trials are insufficient to give a definite answer to these questions...
October 2005: Pneumologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"